Navigation Links
Reportlinker Adds Nanobiotechnologies - Applications, Markets and Companies
Date:4/4/2011

NEW YORK, April 4, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Nanobiotechnologies- applications, markets and companies

http://www.reportlinker.com/p0203545/Nanobiotechnologies--applications-markets-and-companies.html

Nanotechnology is the creation and utilization of materials, devices, and systems through the control of matter on the nanometer-length scale (a nanometer is one billionth of a meter. Nanobiotechnology, an integration of physical sciences, molecular engineering, biology, chemistry and biotechnology holds considerable promise of advances in pharmaceuticals and healthcare. The report starts with an introduction to various techniques and materials that are relevant to nanobiotechnology. It includes some of the physical forms of energy such as nanolasers. Some of the technologies are scaling down such as microfluidics to nanofluidic biochips and others are constructions from bottom up. Application in life sciences research, particularly at the cell level sets the stage for role of nanobiotechnology in healthcare in subsequent chapters.

Some of the earliest applications are in molecular diagnostics. Nanoparticles, particularly quantum dots, are playing important roles. In vitro diagnostics, does not have any of the safety concerns associated with the fate of nanoparticles introduced into the human body. Numerous nanodevices and nanosystems for sequencing single molecules of DNA are feasible. Various nanodiagnostics that have been reviewed will improve the sensitivity and extend the present limits of molecular diagnostics.

An increasing use of nanobiotechnology by the pharmaceutical and biotechnology industries is anticipated. Nanotechnology will be applied at all stages of drug development - from formulations for optimal delivery to diagnostic applications in clinical trials. Many of the assays based on nanobiotechnology will enable high-throughput screening. Some of nanostructures such as fullerenes are themselves drug candidates as they allow precise grafting of active chemical groups in three-dimensional orientations. The most important pharmaceutical applications are in drug delivery. Apart from offering a solution to solubility problems, nanobiotechnology provides and intracellular delivery possibilities. Skin penetration is improved in transdermal drug delivery. A particularly effective application is as nonviral gene therapy vectors. Nanotechnology has the potential to provide controlled release devices with autonomous operation guided by the needs.

Nanomedicine is now within the realm of reality starting with nanodiagnostics and drug delivery facilitated by nanobiotechnology. Miniature devices such as nanorobots could carry out integrated diagnosis and therapy by refined and minimally invasive procedures, nanosurgery, as an alternative to crude surgery. Nanotechnology will markedly improve the implants and tissue engineering approaches as well.

There is some concern about the safety of nanoparticles introduced in the human body and released into the environment. Research is underway to address these issues. As yet there are no FDA directives to regulate nanobiotechnology but as products are ready to enter market, these are expected to be in place.

Future nanobiotechnology markets are calculated on the basis of the background markets in the areas of application and the share of this market by new technologies and state of development at any given year in the future. This is based on a comprehensive and thorough review of the current status of nanobiotechnology, research work in progress and anticipated progress. There is definite indication of large growth of the market but it will be uneven and cannot be plotted as a steady growth curve. Marketing estimates are given according to areas of application, technologies and geographical distribution starting with 2010. The largest expansion is expected between the years 2015 and 2020.

Profiles of 245 companies, out of over 500 involved in this area, are included in the last chapter along with their 188 collaborations. The report is supplemented with 41 Tables, 21 figures and 700 references to the literature.

Table of contents

Technologies

Applications in life sciences

Nanomolecular diagnostics

Nanobiotechnology in drug discovery & development

Nanobiotechnology in drug delivery

Clinical applications of nanobiotechnology

Regulatory and safety issues

Markets

Companies

To order this report:

Nanobiotechnologies- applications, markets and companies

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

CONTACT:  
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: +1-805-652-2626
Intl: +1-805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Reportlinker Adds Molecular Diagnostics Markets
2. Reportlinker Adds Upstream Processing in Biopharmaceuticals - Increasing Use of Low-Cost Disposable Bioreactors to Drive the Upstream Bioprocessing Market
3. Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment
4. Reportlinker Adds Quantum Dots: Technologies and Global Markets
5. Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry
6. Reportlinker Adds Global Nanobiotechnology Industry
7. Reportlinker Adds Global Biochips Industry
8. Reportlinker Adds Diabetic Retinopathy Therapeutics - Pipeline Assessment and Market Forecasts to 2017
9. Reportlinker Adds World Market for Molecular Diagnostics: Potential and Reality, Whats Hot and Whats Not , The
10. Reportlinker Adds Three Alternative Scenarios of the Future In Vitro Diagnostics Market through 2018
11. Reportlinker Adds The 2011 Clinical Chemistry and Immunodiagnostics Markets: US, Europe, Japan; Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... At its ... announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief research scientist of ... been selected for membership in ARCS Alumni Hall of Fame . ASTER ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ComplianceOnline’s Medical Device ... on 7th and 8th June 2018 in San Francisco, CA. The Summit brings together ... as several distinguished CEOs, board directors and government officials from around the world to ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today ... designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) ... able to cross the cell membrane and bind intracellular STAT3 and inhibit its ...
Breaking Biology Technology:
(Date:4/24/2017)... Janice Kephart , former 9/11 ... Partners, LLP (IdSP) , today issues the following ... March 6, 2017 Executive Order: Protecting the ... be instilled with greater confidence, enabling the reactivation ... applications are suspended by until at least July ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... its 2016 Annual Report on Form 10-K on Thursday April 13, ... ... the Investor Relations section of the Company,s website at http://www.nxt-id.com ... http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, ... secure authentication solutions, today announced that it has ... Advanced Research Projects Activity (IARPA) to develop next-generation ... program. "Innovation has been a driving ... Thor program will allow us to innovate and ...
Breaking Biology News(10 mins):